Skip to main content

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study

*March 2023*


  • Lazertinib showed comparable efficacy and safety in real-world clinical settings.
  • Lazertinib demonstrated durable disease control both systematic and intracranially.
  • The most common adverse event was paresthesia which was manageable by dose modification.
  • Further development of lazertinib in 1st┬áline is highly warranted.

Read more.